BioLineRx (BLRX) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for BioLineRx (NASDAQ: BLRX):

  • 8/9/2017 – BioLineRx was given a new $4.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/9/2017 – BioLineRx was given a new $3.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 8/8/2017 – BioLineRx was given a new $3.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 8/4/2017 – BioLineRx is now covered by analysts at Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $3.00 price target on the stock.
  • 8/3/2017 – BioLineRx is now covered by analysts at Roth Capital. They set a “buy” rating and a $3.00 price target on the stock.
  • 7/26/2017 – BioLineRx was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
  • 7/17/2017 – BioLineRx was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/10/2017 – BioLineRx was given a new $3.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 6/20/2017 – BioLineRx was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “sell” rating. According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Shares of BioLineRx Ltd. (NASDAQ:BLRX) opened at 1.18 on Thursday. BioLineRx Ltd. has a 1-year low of $0.80 and a 1-year high of $1.42. The stock’s 50 day moving average price is $0.94 and its 200-day moving average price is $0.97. The stock’s market cap is $72.90 million.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.05). On average, equities research analysts forecast that BioLineRx Ltd. will post ($0.24) earnings per share for the current year.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Receive News & Ratings for BioLineRx Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply